NCT01305512View on ClinicalTrials.gov

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions
Solid Tumor in Advanced Stage
Interventions
DRUG

SPARC1028

SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest

Trial Locations (1)

Unknown

SPARC Site 1, Buffalo

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT01305512 - Pharmacokinetic, Safety and Tolerability Study of SPARC1028 | Biotech Hunter | Biotech Hunter